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Abstract
Introduction: Strategies employing a single rapid diagnostic test (RDT) such as HIV self-testing (HIVST) or “test for triage”
(T4T) are proposed to increase HIV testing programme impact. Current guidelines recommend serial testing with two or three
RDTs for HIV diagnosis, followed by retesting with the same algorithm to verify HIV-positive status before anti-retroviral ther-
apy (ART) initiation. We investigated whether clients presenting to HIV testing services (HTS) following a single reactive RDT
must undergo the diagnostic algorithm twice to diagnose and verify HIV-positive status, or whether a diagnosis with the set-
ting-specific algorithm is adequate for ART initiation.
Methods: We calculated (1) expected number of false-positive (FP) misclassifications per 10,000 HIV negative persons tested,
(2) positive predictive value (PPV) of the overall HIV testing strategy compared to the WHO recommended PPV ≥99%, and
(3) expected cost per FP misclassified person identified by additional verification testing in a typical low-/middle-income set-
ting, compared to the expected lifetime ART cost of $3000. Scenarios considered were as follows: 10% prevalence using two
serial RDTs for diagnosis, 1% prevalence using three serial RDTs, and calibration using programmatic data from Malawi in
2017 where the proportion of people testing HIV positive in facilities was 4%.
Results: In the 10% HIV prevalence setting with a triage test, the expected number of FP misclassifications was 0.86 per
10,000 tested without verification testing and the PPV was 99.9%. In the 1% prevalence setting, expected FP misclassifications
were 0.19 with 99.8% PPV, and in the Malawi 2017 calibrated setting the expected misclassifications were 0.08 with 99.98%
PPV. The cost per FP identified by verification testing was $5879, $3770, and $24,259 respectively. Results were sensitive to
assumptions about accuracy of self-reported reactive results and whether reactive triage test results influenced biased inter-
pretation of subsequent RDT results by the HTS provider.
Conclusions: Diagnosis with the full algorithm following presentation with a reactive triage test is expected to achieve PPV
above the 99% threshold. Continuing verification testing prior to ART initiation remains recommended, but HIV testing strate-
gies involving HIVST and T4T may provide opportunities to maintain quality while increasing efficiency as part of broader
restructuring of HIV testing service delivery.
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1 | INTRODUCTION
Substantial scale-up of HIV testing services (HTS) has con-
tributed to tremendous progress towards global targets to
diagnose 90% of people with HIV by 2020. In 2017, PEPFAR
alone conducted more than 85 million HIV tests [1]. Despite
this scale-up, an estimated 25% of people with HIV remain
unaware of their status [2].
Striving for these ambitious targets for HIV diagnosis, while
also seeking increases in the efficiency and effectiveness of
services, has stimulated innovative approaches to providing
HTS. Recent forecasts suggest the HIV response is not on
track to achieve the 90-90-90 testing and treatment targets
unless significant investments are made [3], and there are
increases in effectiveness and efficiency of services. The
expanded volume of HIV testing and depletion of undiagnosed
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persons has increased the marginal testing cost per HIV-posi-
tive person identified. Static donor investment has also added
pressures to implement more “cost-effective” testing
approaches. As a result, many countries are looking for inno-
vative ways to continue to scale-up HIV testing, while maxi-
mizing effectiveness and efficiency and maintaining quality.
To establish a diagnosis of HIV infection, WHO Guidelines
recommend using multiple independent serological assays
(rapid diagnostic tests (RDTs) and enzyme immunoassays) [4].
Each assay must demonstrate at least 99% sensitivity and
98% specificity. In settings where the prevalence among HTS
clients is above 5%, guidelines recommend reactive results
from two consecutive assays conducted serially to establish
HIV infection, and three consecutive assays in settings with
HIV prevalence below 5% (Figure 1A), ensuring a positive pre-
dictive value (PPV) of above 99% in all settings [4]. If the
results of the assays are discrepant, both assays are repeated.
In the high prevalence setting (≥5%), if still discrepant, a third
assay is applied. If the third assay is non-reactive, the result is
reported as HIV negative, while if reactive the result is
reported as inconclusive to be retested in 14 days. In the low
prevalence setting, all three assays must be reactive to estab-
lish HIV infection; if the first two are reactive and the third
non-reactive, the result is reported as inconclusive for re-test-
ing in 14 days.
Recent reports have described suboptimal quality of HIV
testing and cases of HIV misdiagnosis [5], highlighting the
importance of ensuring reliable and accurate HIV testing,
alongside scale-up. A recent systematic review identified the
main reason for false-positive (FP) HIV diagnosis was the use
of incorrect or suboptimal testing strategies and algorithms in
facilities [6]. To mitigate misclassification of HIV status (often
due to human error), WHO recommends re-testing with the
full diagnostic algorithm by an independent provider to “verify”
HIV-positive status immediately prior to anti-retroviral therapy
(ART) initiation (Figure 1B) [4]. Recent analyses estimated that
additional verification testing prior to ART initiation is highly
cost-saving [6,7], in addition to being good public-health prac-
tice, but many countries are yet to implement this approach
[8].
HIV self-testing (HIVST) and “test for triage” (T4T) are two
testing modalities that both involve provision of a single HIV
RDT, referred to as an “A0” (assay 0) test, either by oneself
(HIVST) or a lay-provider in a community-based setting (T4T).
Clients with reactive A0 RDT results are linked to the health
system for testing with the full national testing algorithm to
Figure 1. Simplified flow diagram for alternative HIV testing and diagnosis strategies prior to ART initiation.
(A and B) represent current “status quo” HIV testing strategies without and with verification testing prior to ART initiation, respectively. (C and
D) illustrate potential testing strategies for clients presenting to HIV testing services (HTS) following a single reactive RDT through HIV self-test-
ing or test for triage modalities. In (C and D), the “A0” assay represents a single RDT, either HIVST or T4T, applied before referral to HIV testing
services for testing and diagnosis with the full diagnostic algorithm. Assays “A1,” “A2,” and “A3” represent HIV antibody rapid diagnostic test (RDT)
conducted in serial comprising a testing algorithm in a setting using a 2-test strategy or 3-test strategy. The “A3” assay is shaded to indicate that
this assay is only applied in a setting using a 3-test strategy for HIV diagnosis (recommended for prevalence <5%). HIV diagnosis is established
only if all two/three serial RDTs are reactive. Discordant results (A1 reactive/A2 non-reactive) should be re-tested using the same two assays; if
they remain discrepant, the result is reported as HIV-inconclusive and the client is retested in 14 days. Full details of the flow and reporting of
results in the case of discrepant results are described in [4]. In our simplified simulation, it is assumed that discrepant results will be adjudicated
correctly upon retesting, and thus FP misclassification only occurs if the results of all two or three assays are misclassified as reactive in serial.
ART, anti-retroviral therapy; HIVST, HIV self-testing; HTC, HIV testing and counselling; RDT, rapid diagnostic test.
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confirm HIV-positive status. Such strategies offer opportuni-
ties to reach those with a single RDT who may not otherwise
test and then promote to further testing and treatment link-
age for those with a reactive test result [4,9]. HIVST has been
highlighted as an effective way to increase uptake and fre-
quency of testing in high risk populations [10]. These
approaches offer the opportunity to improve quality and
efficiency in the health system, including fast-tracking those
with reactive results to care and those who are negative to
prevention [4,9]. In the light of evidence suggesting subopti-
mal specificity of HTS [6] and recent evidence that HIVST is
highly specific [11], many countries rolling out HIVST are con-
sidering whether additional verification testing is still required
before ART initiation for people presenting to care following a
reactive HIVST result.
This analysis considers whether patients with a single reac-
tive A0 RDT, from either HIVST or T4T, must undergo the full
testing strategy twice (1) for diagnosis and (2) for verification
testing prior to ART initiation, or if is it adequate to initiate
ART following an initial reactive A0 result followed by a diag-
nosis with the full testing strategy alone (i.e. without additional
verification of HIV status at ART initiation, hereafter verifica-
tion testing).
2 | METHODS
We used a simple probability model to calculate the expected
levels of FP misclassification arising from HIV testing strategies
that included an A0 RDT prior to presenting for HTS compared
to current HIV testing strategies that do not include an A0
test. The model extends a previously developed model of WHO
recommended HIV testing strategies, including verification
testing, to incorporate a single RDT as an A0 T4T [6]. All analy-
ses were conducted in R version 3.5.0. An R script reproducing
all analyses is provided as Data S1.
2.1 | Testing strategies considered
Figure 1 presents the four testing strategies considered. The
first two (A and B) are “status quo” HIV testing strategies
without or with verification testing before ART initiation (Fig-
ures 1A and 1B respectively); WHO HTS Guidelines recom-
mend testing including verification (Figure 1B). The HTS client
is considered “diagnosed” following reactive results on two
independent RDTs (A1 + A2) in a setting with prevalence
above 5% or three independent RDTs (A1 + A2 + A3) in a
setting with prevalence below 5%. Following diagnosis, the cli-
ent is referred for HIV care and treatment at which point the
full two-test or three-test HIV testing strategy is repeated to
verify the HIV status (Figure 1B), followed by ART initiation if
the HIV diagnosis is confirmed.
In the third strategy (Figure 1C), we considered that clients
underwent an A0 test with a reactive result prior to presenta-
tion at HTS. Following this they proceed through the full diag-
nosis and verification before initiating ART. In the fourth
strategy, we considered combining the “diagnosis” and “verifi-
cation” stages for clients presenting for HTS following a reac-
tive A0 test (Figure 1D). That is, they are initiated to ART
following a single sequence of two or three reactive RDTs per
the validated national testing algorithm.
2.2 | Modelled scenarios and assumptions about
RDT performance in diagnostic settings
As base scenarios, we considered a “high-prevalence” setting
using a two-test strategy with 10% HIV prevalence among
testing clients and a “low-prevalence” setting employing a
three-test strategy with 1% HIV prevalence. Consistent with
previous application of our model [6], we assumed 98% speci-
ficity of each RDT in the algorithm, which is the minimum
specificity required for WHO prequalification [12]. We further
assumed a 20% probability that a FP misclassification on one
RDT would also be misclassified on the subsequent indepen-
dent RDT [6]. This is due to potential correlated exogenous
factors that might influence correlated FP classification errors,
such as environmental conditions or user errors affecting the
outcome of both tests. The specificity for the overall testing
algorithm (A1 + A2 or A1 + A2 + A3) is calculated as one
minus the probability that both or all three assays are reactive
given the true status is HIV negative:
spec2test ¼ 1 1 specA1ð Þ  cþ 1 cð Þ  1 specA2ð Þð Þ
spec3test ¼ 1 1 specA1ð Þ 

cþ 1 cð Þ  1 specA1ð Þ
 cþ 1 cð Þ  1 specA3Þð Þð Þ
where specAx = 0.98 is the specificity for each individual
assay and c = 0.2 is the additional probability that a FP mis-
classification one on RDT results in a misclassification on the
next RDT in the algorithm. These assumptions imply overall
testing algorithm specificity of spec2-test = 99.57% for the
two-test strategy and spec3-test = 99.91% for the three-test
strategy.
We considered a third scenario indicative of the perfor-
mance of the national HIV testing programme of Malawi in
2017. Malawi currently uses a two-test strategy and has con-
ducted verification testing prior to ART initiation since 2011.
The national HIV prevalence among adults in 2017 was 10%
[13], the positivity among HTS clients was 4% across all test-
ing modalities including health facilities, non-health facility
venues, mobile testing, and community-based testing [14].
According to 2017 verification testing records, of the 174,078
clients testing positive and undergoing verification, 1481 (1%)
were subsequently found to be HIV negative of the 174,078
testing HIV positive and undergoing verification [14]. The
prevalence among testers of 4% and PPV of 99% imply that
the specificity for the two-test algorithm is 99.96%.
2.3 | Assumptions about performance of A0 tests
We assumed a specificity of 98% for A0 tests conducted via
HIVST or T4T modalities as a base assumption and varied
specificity from 90% to 100% in sensitivity analyses [11]. In
our base analysis, we assumed that the outcome of the A0
test does not affect accuracy of subsequent diagnostic testing
conducted by an HTS provider. However, in sensitivity analysis
we considered the potential effect of knowledge of the A0
test result influencing reader error resulting in FP misclassifi-
cation by the HTS provider. In sensitivity analysis, we mod-
elled a probability ranging from 0% to 20% that the A1 test
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would be misclassified for an HIV-negative individual present-
ing for HTS following a FP A0 triage test result. We report
results focused on 0% and 5% probability of reader error.
2.4 | Cost assumptions
We assumed a cost of $7 per client for verification retesting
with the three-test strategy and $5 per client for verification
retesting with the two-test strategy, informed by HIV testing
cost data typical for sub-Saharan Africa [15]. We estimated
the discounted lifetime ART cost of $3000. This was based on
an annual cost of $150 per year in sub-Saharan Africa includ-
ing ARV commodities, diagnostics, and clinical monitoring, and
service delivery for stable ART patients [16] over 30 years life
expectancy discounted at 3% per annum [17] assuming no loss
to follow-up. All costs were considered in 2016 US dollars.
2.5 | Analysis
For each testing strategy and scenario (“high prevalence”—
10%, “low prevalence”—1%, “Malawi 2017”—4%), we calcu-
lated three outcomes of interest:
(1) The expected number of FP misclassifications per 10,000
HIV-negative persons tested.
(2) The expected PPV for the overall testing strategy, that is,
the probability that a person initiated on ART is truly HIV
positive.
(3) The expected cost per FP person identified through verifi-
cation re-testing compared to the expected lifetime cost
of ART.
For the calculation of PPV, we conservatively assumed a
sensitivity of 90% among HIV-positive clients, such that:
PPV ¼ sens  prev
sens  prevþ 1 specstrgyð Þ  1 prevð Þ
where specstrgy is the specificity of the overall testing strat-
egy including any A0 test or verification testing. We consid-
ered testing strategies “acceptable” if the PPV for the overall
testing strategy was above the 99% threshold defined by the
WHO Guidelines [15].
We considered additional verification testing “cost-efficient”
if the cost per FP misclassification identified was less than the
expected lifetime ART cost of $3000. The total cost of verifi-
cation testing was the cost per client for verification testing
($5 or $7 depending on 2-test or 3-test algorithm) times the
number of clients classified as HIV positive before verification
testing:
½verification cost ¼ cost per verification client½ 
 sens  prevþ 1 specnoverifð Þ  1 prevð Þð Þ
The expected number of false positive cases identified
through verification testing was calculated as the number of
negative clients testing times the specificity of the strategy
with verification testing minus the specificity of the same
strategy without verification testing:
½FP identified ¼ 1 prevð Þ  specw=verif  specnoverif
 
The cost per FP identified was the ratio of total verification
cost divided by the number of FP identified.
3 | RESULTS
3.1 | Rates of false positive misclassification
3.1.1 | Scenario 1: High prevalence (10%)
In scenario 1, with 10% HIV prevalence and using the two-
test strategy, the “status quo” scenario of HIV diagnosis fol-
lowing reactive A1 and A2 RDTs without additional verifica-
tion testing (Figure 1A) resulted in 43.2 FP misclassifications
per 10,000 HIV-negative persons tested (Table 1). Implement-
ing verification testing by retesting using the full testing strat-
egy (Figure 1B) reduced the number of misclassifications to
0.64. The PPV increased from 95.9% to 99.9%.
When HTS clients had a reactive A0 triage test prior to full
diagnosis at HTS, the expected number of misclassifications
was only 0.86 and the PPV was 99.9% without additional veri-
fication testing (Figure 1D). Additional verification testing (Fig-
ure 1C) reduced the number of misclassifications to 0.01.
When we assumed that a false-reactive A0 RDT may induce a
5% probability of reader error of the A1 RDT at HTS, the
expected number of FP for the diagnosis without additional
verification increased to 3.0, but the PPV was 99.7%, remain-
ing well above the 99% target threshold.
3.1.2 | Scenario 2: Low prevalence (1%)
In scenario 2, with 1% HIV prevalence and using the a three-
test strategy, the expected number of FP misclassifications
was lower for all strategies due to the inclusion of the third
RDT, but the PPV was also slightly lower due to the lower
prevalence (Table 1). The number of FP for HIV diagnosis fol-
lowing a single application of the three-test algorithm was 9.3
and the PPV was 90.7%. For clients presenting with a reactive
A0, the number of FP reduced to 0.2 and the PPV was 99.8%.
Assuming a 5% error for the A1 test following a false-reactive
A0 changed the expected FP to 0.6 and the PPV to 99.3%,
still above the 99% threshold.
3.1.3 | Scenario 3: Malawi 2017 (4% positivity; 99%
PPV)
In the scenario based on programmatic data from Malawi in
2017, in which HIV positivity among HTS clients was 4% and
the two-test strategy performed with a 99% PPV, the
expected number of FP misclassifications was 4.2 per 10,000
HIV-negative persons tested. The number of FP reduced to
0.08 with a 99.98% PPV for clients presenting with a reactive
A0, or 2.1 FP and a 99.5% PPV when we assumed a 5%
reader error for the A1 RDT.
3.2 | Cost per false positive identified
Without A0 triage testing before presentation for HTS (“sta-
tus quo” scenario), additional verification testing was clearly
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cost-efficient. The estimated cost per FP misclassification iden-
tified was $123, $75, and $460 for the “high prevalence,” “low
prevalence” and “Malawi 2017” scenarios respectively
(Table 1), which compared very favourably to the $3000
expected lifetime cost had the misclassified client been initi-
ated on ART. When clients presented for HTS following a
reactive A0 RDT, the cost per FP identified was $5880 in the
base case 10% prevalence setting, $3428 in the 1% preva-
lence setting, and $22,743 for the Malawi 2017 HTS assump-
tions. The cost per FP identified was lower when assuming 5%
reader error in the A1 RDT at $1708, $999, and $909
respectively, but still markedly higher than the cost per FP
identified associated with verification testing in the absence of
the A0 triage test.
3.3 | Sensitivity analysis of A0 specificity
Figure 2 considers the sensitivity of these conclusions to
assumptions about the specificity of the A0 triage test,
assumed to be 98% in the base-case analysis in Table 1. For
specificity values ranging between 90% and 100%, the
expected number of FP cases is higher and PPV lower for
lower A0 specificity, but in all cases the PPV is well above the
99% PPV target threshold. Figure 3 considers the sensitivity
to the assumed probability of reader error misclassification of
the A1 test following attendance with a reactive A0 triage
test, which was assumed to be 0% or 5% in Table 1. Higher
probabilities of reader error associated with a FP A0 result
reduced the performance of the overall testing strategy, and
at high levels of error additional verification testing may be
needed to meet the 99% PPV target threshold. In the Malawi
2017 scenario, in which the specificity of the A1 test was
higher than the 98% assumed in the baseline scenario, HTS
performance could be worse than the status quo without
verification testing if a FP A0 test resulted in greater than
10% reader error in A1 test results, and this threshold would
vary depending on the attained specificity of the A0 test.
4 | DISCUSSION
The recommendation for verification of HIV status before
ART initiation has been increasingly adopted to ensure the
fidelity of the HIV testing and ART programmes and avoid
future costs and ramifications associated with inadvertently
initiating HIV-negative persons on lifelong ART. Previous stud-
ies have highlighted that retesting may be particularly impor-
tant considering reports of poor quality testing and low
uptake of WHO-recommended HIV testing strategies and
algorithms [5,18-21]. Policy analysis from 2015 suggested
fewer than 20% of reporting countries had a national testing
strategy and algorithm that was in full alignment with WHO
guidelines [8].
In this analysis, we considered whether such additional veri-
fication testing is required and cost-efficient for clients who
already underwent diagnostic testing to confirm their HIV sta-
tus in HTS following a reactive triage test. Taken together, our
analysis suggests triage test approaches, including HIVST, can
potentially result in lower FP HIV misclassification in settings
not implementing verification testing prior to ART. We find
that the rate of FP misclassification is expected to be very
low for persons presenting with a reactive HIVST confirmed
by diagnostic testing and the PPV is expected to be well
above 99% without additional verification testing. This is the
case even with base assumptions about the accuracy of HTS
that appear conservative compared to programmatic data
about the current performance of HIV testing in program-
matic settings. Given the very small number of clients
Table 1. Results for number of false positive misclassifications, PPV, and cost per FP identified for alternative scenarios and testing
strategies
10% prevalence 1% prevalence Malawi 2017a
Status Quo With A0
A0, 5%
A1 error Status Quo With A0
A0, 5%
A1 error Status Quo With A0
A0, 5%
A1 error
Testing Strategy Two-test Three-test Two-test
Algorithm specificity 99.57% 99.91% 99.96%
Verification testing cost $5 $7 $5
False positive misclassifications per 10,000 HIV negative persons tested
No verificationb 43.2 0.86 2.98 9.3 0.19 0.64 4.18 0.08 2.10
With verificationc 0.64 0.01 0.04 0.03 0.001 0.002 0.04 0.001 0.02
PPV
No verificationb 95.86% 99.91% 99.70% 90.69% 99.80% 99.30% 98.90% 99.98% 99.44%
With verificationc 99.94% >99.99% >99.99% 99.97% >99.99% >99.99% 99.99% >99.99% 99.99%
Cost per FP identifiedd $123 $5,880 $1,708 $75 $3,428 $999 $460 $22,743 $909
FP, false-positive; PPV, positive predictive value.
aPrevalence among HIV testing clients was 4% in Malawi in 2017. HIV prevalence among all adults was approximately 10%.
b“No verification” corresponds to strategy in Figure 1A under “status quo” scenario and Figure 1D for “with A0” scenarios.
c“With verification” corresponds to Figure 1B under “status quo” scenario’ and Figure 1C under “with A0” scenarios.
dCost per FP identified through verification testing compared to no verification testing. Cost is calculated as the expected number of verification
tests conducted (sens 9 prev + (1  spec) 9 (1  prev)) times the cost per verification test divided by the number of FP cases identified
through verification testing.
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Figure 2. Sensitivity analysis of assumptions the specificity of the A0 RDT on the expected number of false positive misclassifications per
10,000 HIV negative persons tested (A to C) and the positive predictive value (PPV) of the overall testing strategy, conservatively assuming
90% sensitivity (D to F).
Red line illustrates scenario in which clients present to HTS following a reactive test and undergo the national HIV testing algorithm once (Fig-
ure 1D). Red points mark the assumed 98% specificity assumed in the base-case analysis. For benchmarking, the blue horizontal line indicates the
results for status quo HIV testing without verification testing (Figure 1A) and the green line indicates status quo testing with verification testing
(Figure 1B). For PPV results (D to F), the grey dashed line indicates the 99% PPV threshold recommended by WHO Consolidated HIV Testing
Guidelines. RDT, rapid diagnostic test.
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Figure 3. Sensitivity analysis about the probability of excess reader error for A1 test if presenting following a false-reactive result of the A0
RDT. (A to C) illustrate the effect on the expected number of false positive misclassifications per 10,000 HIV negative persons tested and
(D to F) illustrate the positive predictive value (PPV) of the overall testing strategy, conservatively assuming 90% sensitivity.
Red line illustrates scenario in which clients present to HTS following a reactive A1 test and undergo the national HIV testing algorithm once (Fig-
ure 1D). For benchmarking, the blue horizontal line indicates the results for status quo HIV testing without verification testing (Figure 1A) and
the green line indicates status quo testing with verification testing (Figure 1B). For PPV results (D to F), the grey dashed line indicates the 99%
PPV threshold recommended by WHO Consolidated HIV Testing Guidelines. HTS, HIV testing services; RDT, rapid diagnostic test.
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expected to be identified as FP, verification testing may not be
cost-efficient relative to the lifetime costs of ART for FP per-
sons.
Even with imperfect specificity of HIVST, the expected num-
ber of FP among persons presenting for HTS following a reac-
tive HIVST is far lower than would be expected amongst a
population of HTS clients who had not undergone triage test-
ing. Most basically, this conclusion reflects the difference in
the prior probability that a client is truly HIV positive before
presenting to HTS. In the absence of triage testing, with a
true HIV positivity of 5% among those testing, 95% of clients
will be truly HIV negative, leaving a large pool among which a
FP misclassification could occur. Among 100 HTS clients pre-
senting following a reactive HIVST with 98% specificity, only
2% would be truly HIV negative, a much smaller group among
whom a FP misclassification could occur.
Our analysis has several limitations and the findings should
be considered in the light of important uncertainties about
key assumptions. First, findings were sensitive to whether we
assumed that presenting with a reactive A0 test might bias
the provider in interpreting results of subsequent A1 RDT
results. Currently, even in relatively high HIV prevalence set-
tings, the large majority (>95%) of HTS clients are classified
as HIV negative following a single RDT. This would change for
a provider seeing a large number of clients referred to care
following a reactive HIVST or T4T. This could change the prior
expectations of the provider about the likely outcome of the
test and subtly bias the interpretation of inconclusive test
results. However, to our knowledge, evidence is not yet avail-
able to evaluate whether this occurs. We consider this a high
priority evidence gap for further research as HIVST scales up.
Second, our analysis takes a narrow perspective on the poten-
tial costs and consequences of FP misclassification by consider-
ing only the costs to the health system associated with lifetime
ART for a misdiagnosed client. Costs and adverse consequences
born by clients may be substantially greater, including unneces-
sary care and treatment, consequences for family, marriages,
and relationships, potential adverse effects of ART.Without cap-
turing the full health and quality of life consequences of HIV
misclassification, we are not able to undertake cost-effective-
ness analysis to benchmark investments in verification testing
against other potential allocation of health resources. More
broadly, cases of FP misclassification may serve to undermine
confidence and engagement in the health system outstripping
the economic costs of unnecessary treatment.
Third, we considered only the risk of false positive diagnosis
amongst HIV-negative clients. Ensuring highly accurate HIV
diagnosis is paramount for HIV testing services. Evidence sug-
gests that rates of false negative misclassification in both tra-
ditional HTS and HIVST are also higher than would be
expected given 99% sensitivity required for WHO prequalifi-
cation [11,22]. Quantifying the rates, reasons, and conse-
quences of false negative diagnosis is an important area for
further implementation research and modelling.
These modelling results need to be considered in the light
of practical implementation issues. Although the expected
number of FP misclassifications identified through verification
testing was low for persons presenting following HIVST, it is
not recommended to discontinue verification testing for these
clients in settings where verification testing is already in place,
working well, and achieving results. It will be important to
review data from settings where this new testing strategy is
used before suggesting changing current recommended prac-
tice. For example, in 2015, Malawi was one of few countries
implementing WHO recommended testing strategies and veri-
fication testing among people with HIV prior to starting ART
[4,8]. These efforts combined with updated guidelines and re-
training of testers, decreased HIV-negative test results follow-
ing an initial HIV-positive diagnosis from 7% to 1% between
2014 and 2016 [14]. Additional studies have highlighted the
role of retesting, alongside validation of national algorithms, to
ensure quality [18,20].
The HIV testing resources required for verification testing is a
small proportion of the overall HIV testing resources, consider-
ing that the very large majority of HTS clients will be classified as
HIV negative from the first assay in the HIV testing algorithm [6].
This will especially be the case as positivity and number of new
diagnoses decline as a share of all those tested. Currently HIVST
is not available at national scale in most settings, and proposing
different models for diagnosis, verification, and treatment initia-
tion for these few HIVST clients may potentially increase frag-
mentation of HTS, which could increase opportunities for errors.
Broader changes in future HTS delivery may reconsider the role
of verification vis-a-vis the “test-for-triage” model in which a sin-
gle RDT is applied at the first engagement with HIV testing ser-
vices, following which clients are referred to HIV care and
treatment facilities for full diagnostic testing with the full national
HIV testing algorithm. For example, embracing the “test-for-
triage” model across all HIV testing modalities, whether facility-
based or community-based may simplify and streamline the pro-
vision of HTS, and harmonize client flow for HIVST clients with
those engaging through other modalities. Such approaches
should be considered and evaluated in programmatic settings.
Programmatically, it may be most advantageous to promote
T4T and HIVST as simplified initial screening tests on a large
scale and deliver quality-assured verification testing directly
before ART initiation at health facilities, cutting out the need
for parallel “intermediate” confirmation testing at peripheral
testing sites.
5 | CONCLUSIONS
Following WHO testing strategies with verification testing prior
to ART initiation is recommended and should be continued. T4T
and HIVST approaches could potentially improve accuracy and
quality of HTS in settings not implementing diagnostic testing
followed by repeated verification testing prior to ART. T4T fol-
lowed by diagnosis with full national testing algorithm is
expected to deliver accurate results above WHO benchmarks
for PPV of at least 99%, so long as the quality and specificity of
HTS remains similar to current programmatic performance.
While HIVST scale-up may render verification testing before
ART less necessary in high quality programmes, selectively dis-
continuing full diagnosis with the national testing algorithm
before verification testing for a subset of clients who present
following reactive A0 test must be considered agains the risk
risks of additional complexity and potential for increased user
and provider error. T4T and HIVST may provide an opportunity
to restructure HTS delivery and quality assurance systems
which should be explored further and evaluated in programmes
to guide future policy.
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